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The number of laparoscopic liver resections undertaken has increased. However, lesions located 
postero-superiorly are difficult to access. This may be overcome by the novel use of trans-
thoracic port(s). Methods for the safe and transparent introduction of new and modified surgical 
procedures are limited and a summary of these issues, for minimally invasive trans thoracic liver 
resections (MITTLR), is lacking.  
This study aims to understand and summarize technique description, governance procedures and 
reporting of outcomes for MITTLR.  
Methods 
A systematic literature search to identify primary studies of all designs describing MITTLR was 
undertaken.  How patients were selected for the new technique was examined. The technical 
components of MITTLR were identified and summarized to understand technique development 
over time. Governance arrangements (e.g. IRB approval) and steps taken to mitigate harm were 
recorded. Finally, specific outcomes reported across studies were documented.   
Results 
Of 2067 83 screened articles, 16 were included reporting data from 145 patients and six 
countries. Selection criteria for patients was explicitly stated in two papers. No studies fully 
described the technique. Five papers reported ethical approval and three gave details of patient 




Technical outcomes were commonly reported e.g. blood loss (15/16 studies), operative time 
(15/16) and margin status (11/16). Information on patient reported outcomes and costs were 
lacking.  
Conclusions 
Technical details and governance procedures were poorly described. Outcomes focussed on 
short term details alone. Transparency is needed for reporting the introduction of new surgical 





Liver resection for primary and secondary tumours is an effective oncological treatment and is 
increasingly being performed by laparoscopic techniques (1-3). Although systematic reviews 
suggest potential advantages of laparoscopic approaches (such as less blood loss and shorter 
hospital stay) compared to large abdominal wall incisions, the included studies were non-
randomized (4-7). Recently, a single-center randomized controlled trial (RCT) compared open and 
laparoscopic surgery for patients undergoing parenchyma-sparing liver resection (8). This is the 
only reported RCT to compare the two techniques and although the study included over 200 
patients, it was single center thus limiting generalizability. Despite the paucity of evidence, 
guidelines recommend that patients are considered for laparoscopic liver resections wherever 
possible (9).  
Factors that can influence the decision to perform an operation laparoscopically include surgeon 
and multi-disciplinary team (MDT) expertise, center policy, infrastructure and approach to 
innovation (10, 11). Issues such as anatomy also need to be considered. Tumours situated 
posteriorly and superiorly within the liver are difficult to access using standard laparoscopic 
techniques because of the surrounding rib cage and diaphragm (12). In these circumstances, 
many surgeons undertake open surgery with an upper abdominal incision. To overcome these 
challenges, modifications to current minimally invasive techniques have been described. These 
modifications, known as minimally invasive trans-thoracic liver resection (MITTLR), involve 




the laparoscopic abdominal ports. A totally trans-thoracic approach is where all the ports are 
placed through the diaphragm or pleura. The technique was first described in 2003 (13).  
Currently, MITTLR is not in widespread use although early studies often suggest that a the 
technique is promising (14). It is well recognised that patients offered new techniques are highly 
selected (15). In addition, surgeons may under-report adverse events and are overly optimistic 
about innovation (16). The complexity of surgery (e.g. surgeon and team expertise, variations in 
pre- and post-operative management and variations in outcome reporting) poses challenges for 
rigorously evaluating new procedures (11).  
Historically, surgical innovations have often been adopted without adequate evidence of efficacy 
or safety. Without proper evaluation, unevidenced based innovations have the potential to harm 
patients. Therefore,  the Idea, Development, Exploration, Assessment, and Long-term Follow up 
(IDEAL) framework and recommendations were developed to facilitate evaluation of the 
introduction of complex interventional procedures (17, 18). However, there remain concerns 
around the processes of patient selection, information provision to patients, technique 
description (specifically, modifications and their rationale), governance procedures (including 
steps taken to mitigate against harms) and the selection of appropriate outcomes(19, 20).  In 
view of these issues, it is hypothesised that a systematic review of the literature of an innovative 
technique and detailed analysis of reporting of study design and conduct would be valuable to 
understand current methods for surgical innovation and identify areas where further research 
and improvement is needed. To our knowledge, there has not been a previous systematic review 
of MITTLR, and no previous study has assessed the introduction of this new procedure into 




into clinical practice by summarizing technique description, governance procedures and how 
outcomes for MITTLR have been reported. 
Methods 
The methods are based on a published protocol for the analysis of innovative invasive procedures 
(21) and the review was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyzes (PRISMA) guidelines (22). 
Inclusion criteria 
All primary research study designs (e.g. case reports, case series, comparative series) describing 
‘transthoracic’ or ‘transdiaphragmatic’ minimally invasive liver resections for benign or malignant 
conditions in adults or children were eligible for inclusion. Although review articles were not 
included per se, where identified the included studies were cross-referenced to ensure all sources 
of evidence were accessed. Pre-clinical and cadaveric studies were excluded as were 
editorial/expert opinion articles (23). Non-English language papers, Presentations and 
conference abstracts were excluded. Studies reporting outcomes on patients undergoing purely 
laparoscopic (without a trans-thoracic component) resections of postero-superior liver segments 
were excluded as were all duplicate studies. 
Search strategy and study selection 
Searches were undertaken in Medline, Embase, CINAHL (Cumulative Index to Nursing and Allied 
Health Literature), PubMed, Web of Science, the Cochrane Central Register of Controlled Trials, 




April 2018. Search terms for trans-thoracic liver resection were combined using the Boolean 
‘AND’ operator (see Appendix 1). Bibliographies of relevant studies and the “related articles” link 
in PubMed were used to identify additional studies. Search results were imported into EndNote© 
reference management software and de-duplicated.  
 
Data extraction and management 
A customised inclusion/exclusion proforma was developed to screen titles and abstracts. 
Screening was performed independently by at least two of four authors (SP, BGM, NSB, HFR). 
Differences between the authors were resolved by consensus with the study group. When no 
abstract was available, or the details were inadequate to enable a decision about eligibility, the 
full article was reviewed. The full-text versions of papers included after abstract screening were 
accessed for further assessment of their eligibility. Reference lists were manually searched for 
additional relevant articles. Data extraction was undertaken independently by at least two 
authors (SP, BGM, NSB, HFR) using a standardized proforma, and any disagreement resolved by 
consensus and/or discussion with the senior author (JMB). The following categories of data were 
extracted from included papers:  
Characteristics of included studies 
The type of study design, year and journal of publication, country of origin and number of 
participating centers and patients were recorded. If studies reported patient selection criteria 




prevent harm to future patients). Funding details or other potential conflicts of interest were 
documented.    
Technique description and co-interventions: 
The surgical description of the MITTLR technique reported was assessed using a typology which 
allows systematic deconstruction of an intervention to understand the individual surgical 
components and steps (24). This was undertaken because existing guidance (SPIRIT and TIDierR) 
for intervention description in study protocols does not request sufficient detail to understand 
how to reproduce a surgical procedure (25, 26). MITTLR was deconstructed according to its 
component parts (pre skin incision considerations, incision and access, dissection, resection, 
haemostasis, reconstruction, after skin closure and use of adjuncts). Then each paper was studied 
to understand which components had been reported. We also examined the authors’ given 
rationale for changing components or adding or removing them based on their experience. This 
was done for each article chronologically. It allowed us to understand how the technique was 
undertaken and how it evolved over time 
Co-interventions were documented. They were defined as interventions that naturally 
accompany or are associated with the intervention itself and can occur before, during or 
afterwards (27). For example, one lung ventilation using a dual lumen endo-tracheal tube may 
be considered a co-intervention during MITTLR.  




Studies were retrospectively classified into IDEAL stages (17). Each study was then assessed to 
determine whether stage-specific IDEAL guidelines had been followed.  
Surgeon expertise: 
Details of the type of center undertaking the intervention, including previous case volumes any 
workload data were recorded. The number and level of seniority of surgeon(s), including their 
experience with minimally invasive liver surgery and MITTLR, were extracted. Documentation of 
whether any surgical learning curves were described was also recorded.  
Governance arrangements: 
Reporting of information describing governance approvals (ethics committee, hospital clinical 
governance departments, Institutional Review Board [IRB], clinical effectiveness committee and 
National Institute for Health and Care Excellence [NICE]) was documented because of the 
importance of transparent introduction of innovation.  
Details regarding whether patient consent for the novel technique was obtained was recorded, 
specifically examining if patients were informed about the innovative nature of MITTLR. If 
reported, the number of patients declining the intervention was recorded as a measure of patient 
acceptability. Details of any steps taken to mitigate harm were recorded (e.g. whether an 
independent oversight committee reviewed the new procedure and its outcomes). 
Outcome reporting 
Information related to outcome reporting was collected in the following categories: adverse 




time of discharge or death) (28), clinical (e.g. operative time and histological margin status), 
process (e.g. length of stay), patient-reported (report of the status of the patient’s health 
condition that comes directly from the patient, without interpretation of the patient’s response 
by a clinician) (29), and economic outcomes.  It is expected that the types of outcomes reported 
in studies evaluating innovative procedures focus on safety and efficacy – and acceptability to 
surgeon and patient.  
 
Data synthesis and statistical analysis 
Results are summarized in a narrative synthesis. No meta-analysis was performed because the 
purpose of this review was to describe how MITTLR is reported in the surgical literature rather 
than to compare outcomes with either open or laparoscopic liver resections.  
 
Results 
Of 2067 articles, 23 were identified for further review and 16 full papers were included (Figure 
1). 
Characteristics of included studies 
The sixteen studies were performed in six countries and included 145 adult patients. The first 
was reported by a Japanese group in 2003 (13). There were six case reports (30-35) and 10 non-




Eleven papers stated that there were no conflicts of interest. Eight papers declared financial 
conflicts of interest, although only three studies were funded. All three (37-39) were from 
educational grants.  
Technique description and co-interventions: 
 The index paper was a Japanese series describing three cases where tumours were excised using 
a totally trans-thoracic approach (13).   The index paper did not provide a full deconstruction of 
the technique, although some components were well described (patient and port positioning, 
use of intra-operative USS, method of liver transection and specimen extraction). The subsequent 
paper(40) did reference the index paper and provided further understanding of patient 
suitability, anaesthetic co-interventions, port type used, technical factors such as haemostasis 
and use of drains (Table 2). The next paper to reference the index paper was (46) the seventh 
report. One other paper (41) referenced the index paper but neither study provided further 
insight into technique evolution.  
Nine studies cited other papers describing MITTLR but did not reference the index paper (30, 31, 
35-38, 41-43). None of these subsequent papers described each component step in detail and 
minor technical modifications were not documented or justified. It was therefore not possible to 
determine how the technique had evolved with time or whether specific components had 
evolved (Table 2). An opportunity for incremental learning to build upon the initial single centre 
reports was lost.  
Steps of the procedure that were well reported (and continued to be well reported as the 




placements, use of intra-operative ultrasound, liver mobilisation (if required) and parenchymal 
transection. Although most studies described port placement, there were variations between 
studies and hence changes over time were difficult to describe. It was not possible to track 
sequential development of the procedure over time. Items that were poorly reported such as 
‘pre theatre considerations’ and ‘factors causing conversion to open surgery’ continued to be 
poorly reported as the procedure evolved.  
 
Analysis of studies against IDEAL recommendations 
All the studies were single-centre retrospective case studies and were therefore classed as IDEAL 
stage 2a (“procedure under development, performed by a few innovators and early adopters on 
a small number of patients”). Whilst the first paper would ordinarily be categorised as a stage 1 
IDEAL study (i.e. first in human), this paper itself references a ‘non-indexed’ description of the 
first case. No studies made a protocol available for review. Selection criteria and proportion of 
eligible patients selected should also be reported – no papers provided the proportion of eligible 
patients recruited. Whilst patient characteristics and short-term clinical outcomes were generally 
well reported, cases were not reported sequentially and iterative changes to the technique 
(common in IDEAL stage 2a) were not clearly described. Ethical approval was reported in five 
studies and informed consent was not adequately described in any study (Table 3). Learning 
curves and methods to mitigate harm (e.g. mentoring for first few cases) were also not described 





None of the papers disclosed the center-specific caseload for either minimally invasive liver 
surgery or MITTLR. Only one study (44) stated the number of surgeons performing MITTLR (single 
surgeon) and level of seniority of participating surgeon was only provided in one paper (38). 
Furthermore, no studies reported specific training regarding the use of MITTLR for participating 
surgeons, the expertise of the team supporting the surgeon or use of a “preceptorship” during 
introduction of MITTLR to their center.  
Governance arrangements: 
Only five studies (37, 38, 41, 44, 45)reported that they had sought and been given ethical 
approval. Two studies documented registration with an institutional review board or hospital 
clinical governance department (46, 47). Three studies documented informed patient consent 
(37, 38, 48) although specific details about whether patients were informed about the innovative 
nature of MITTLR, and its associated risks, were not provided. None of the remaining papers 
mentioned consent at all. None of the included studies reported the number of patients declining 
the intervention. No studies mentioned any steps taken to mitigate harm and whether 
independent oversight committees reviewed MITTLR and its outcomes.  
Outcome reporting: 
Outcome reporting is summarized in Table 4. Two studies (38, 44) provided an a priori definition 
of adverse events.  
Fifteen studies detailed complications without a single mortality reported. In terms of clinical 
outcomes, most of the studies reported blood loss (15/16) and margin status (11/16) as surrogate 




failure of the minimally invasive trans-thoracic approach and conversion to an open approach. 
Reasons for conversion included bleeding, poor views and concern about tumour margins. 
Operative time (14/16) and length of stay (14/16) were used as descriptors of process in most of 
the studies. Follow up was described in four studies and ranged from 4-61 months. Clinical 
outcomes are summarised in Table 5. 
Patient reported outcomes and cost effectiveness were not measured in any of the studies.  
Three studies drew no conclusion regarding MITTLR practice in the future, three studies felt 
further evaluation was warranted, seven studies felt the procedure was safe and feasible whilst 
three studies concluded that MITTLR should be adopted by surgeons.  
 
Discussion 
This is the first systematic review examining MITTLR. It identified 16 studies that were case 
reports and non-comparative case series. Whilst these small studies showed promising results 
the reporting limits their value to inform practice. Full technical description of the technique was 
lacking from all publications including the index study published in 2003 (13). Limited data on 
patient selection criteria and technique description were available. This means that it is 
challenging for other surgeons (early adopters) to reproduce the technique safely in appropriate 
patients. Errors may be inadvertently repeated. In addition, the governance arrangements 
(including patient consent) and regulatory approvals were poorly reported. Overall, current 
reporting of this innovative and evolving technique was poor and lacks rigor.  Better and more 




adopting the technique can do so ethically and with minimal risk to patients, to optimise safe 
uptake.  
Surgery is a complex intervention making it difficult to evaluate rigorously. The Idea, 
Development, Exploration, Assessment and Long-term Follow-up (IDEAL) framework, developed 
in 2009, is one proposed method for introducing and evaluating new surgical techniques (18). 
None of the reports describing MITTLR adhered to all the IDEAL guidelines, despite 15 of the 16 
studies being published after IDEAL guidance became available. All the included studies would 
retrospectively be categorised as IDEAL stage 2a (development stage), suggesting that the 
technique has not yet stabilised, despite having been first reported over 15 years ago.  There has 
been a lack of incremental learning and stepwise progression over the 15-year period – all 16 
studies were either case reports or non-comparative single-centre, single-surgeon series. An 
opportunity to build upon this work and perform multi-centre studies with short- and long-term 
outcomes to provide insight into the technique has been missed.  Learning curves could have 
been shortened by collaboration between the ‘pioneering’ surgeons to standardise techniques 
and outcomes to be monitored in future studies. This concept has been demonstrated in 
laparoscopic liver surgery where ‘early adopters’ who received specific training with 
standardisation of techniques had a shorter learning curve than the ‘pioneering’ surgeons (50). 
The non-adherence to IDEAL in evaluating MITTLR has may have resulted in reduced compliance 
with governance arrangements (gaining ethical approval and informed consent from patients) 
and poor study design with inadequate reporting of patient selection and technical modifications. 
In this review, it was identified that most studies did not report that ethical (IRB) approval was 




variation of laparoscopic surgery and therefore consider ethical approval unnecessary. A new or 
modified technique, however, could be associated with additional or unknown risks and 
provision of patients with such information is of importance. There may also be requirements to 
inform patients if a surgeon is undertaking a new procedure for the first time or if the technique 
is still evolving as the short and long-term sequalae may not yet be fully defined (51, 52). In 
addition to not reporting whether patient consent for a new procedure was obtained, it was 
noted that publications did not report the impact of the surgical learning curve on outcomes and 
whether steps were taken to mitigate potential harm to the patient as a surgeons’ experienced 
developed.  Methods to mitigate the effects of the learning curve include cadaveric training, 
visiting specialist centers and/or mentoring by visiting surgeons with expertise (53). No 
publications clearly reported how the surgeon’s own experience and learning curve was relayed 
to patients.  
Whilst this study is the largest and most comprehensive review of the literature reporting MITTLR 
to date, it has some limitations. Data from the papers were extracted verbatim and it was 
assumed that if information was not documented it did not happen. In addition, it was not 
possible to contact all authors individually to obtain further information about technique 
evolution and local governance arrangements. It is possible that early adopters may have 
implemented MITTLR in their clinical practise but have not yet published their results. Only full-
text publications were included as it was considered that only these would provide the necessary 
methodological details required to robustly assess technique development, governance 




This study demonstrates significant deficiencies in the introduction of this innovative procedure 
with regards to i) description of patient selection, ii) information provision to patients, iii) 
technique description and iv) governance procedures. Surgical innovators should continue to use 
the IDEAL framework, although descriptions of patient selection, surgical technique, governance 
procedures and outcome reporting need to be optimised to ensure new procedures are 
reproducible.  
To enhance the evaluation and adoption of novel procedures, there is a need to i) identify 
possible benefits early (and equally importantly, identify unsuccessful or harmful procedures so 
that they can be stopped in a timely way); ii) provide good leadership to champion and advocate 
adoption whilst encouraging continuous assessment of outcomes; iii) provide accurate 
descriptions of the technique and careful documentation of when (and why) this evolves; and iv) 
consider how impact will be measured. Information provision to patients detailing the innovative 
nature of the procedure, the surgeon’s experience with the proposed procedure, the risks and 
benefits including uncertainty around risks and alternative treatments, are all crucial (54) .  
Surgical innovation is required to develop novel procedures that improve patient outcomes. 
However, innovation it is important that this is conducted safely and transparently to optimise 
learning and minimise patient harm. Clear guidance and regulatory frameworks that build on 
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Records identified through 
database searching 



























Additional records identified 
through other sources 
(n =1) 
Records after duplicates removed 
(n = 1673) 
Abstracts screened 
(n = 35) 
Records excluded 
(n =13) 
Lung resection n=2 
Conference abstract n=5  
Review articles n=1 
Laparoscopic approach only n=3 
Open approach n=2  
Full-text articles assessed 
for eligibility 
(n = 22) Full-text articles excluded  
(n =6) 
Hand-assisted approach n=1 
Open approach n= 3 
Review articles n=2 
 
Studies included in 
qualitative synthesis 
(n = 16) 
Records excluded (n= 1638)  
Animal studies n= 3 
Conference abstract n= 37 
Letters n= 1 




Table 1; Characteristics of included studies 
Paper number Author Journal Year of publication Country Type of study Patients (N) 
1 Teramoto (13) World Journal of Surgery 2003 Japan NCS 3 
2 Cloyd (40) Surgical Endoscopy 2012 USA NCS  2 
3 Ishizawa (39) Annals of Surgery 2012 France NCS  10 
4 Aikawa (48) Surgical Endoscopy 2014 Japan V/CR 1 
5 Kruger (30) Arquivos Brasileiros de Cirurgia Digestiva 
 
2014 Brazil CR 1 
6 Lee (41) Journal of HBP Sciences 2014 South Korea CS 5 
7 Chiow (44) 
 
HPB Journal 2015 Australia RC 8 
8 Hallet (31) Journal of American College of Surgeons  2015 France CR 1 
9 Ogiso (42) Annals of Surgery 2015 France RC 25 
10 Schwarz (33) Annals of Surgical Oncology 2016 USA V/CR 1 
11 Yamashita (34) Annals of Surgical Oncology 2017 USA V/CR 1 
12 Ichida (37) Surgical Endoscopy  2017 Japan NCS 14 
13 Hirokawa (36) World Journal of Surgery 2017 Japan RC 23 
14 Inoue (38) J Gastrointestinal Surg 2017 Japan RC 32 








** NCS- non-comparative study 
V- video presentation 
CR- Case report 
CS- Case series 












Table 2: Description of component parts of MITTLR by study  
Component  Paper number 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Pre-theater 
considerations  
MDT discussion                 
Radiological criteria for selection                 
Patient suitability                 
Pre-incision anaesthetic 
considerations 
Dual v single lumen ET tube                 
Pre-incision surgical 
considerations 
Stack set up                 
Stack settings                 
Patient positioning                 
Skin preparation                 
Incision and access Induction of pneumoperitoneum                 
Port placement                 
Port types                 
Dissection Intra-operative USS                 
Liver mobilisation (if needed)                 
Inflow control (if needed)                 
Resection Liver parenchyma transection                 
Factors causing conversion to open surgery                 




Insertion of surgical 
adjuncts 
Insertion of abdominal drain                 
Insertion of chest drain                 
Closure Specimen extraction                 
Closure of diaphragm                 
After skin closure Post-operative CXR                 
Removal of chest drain                 
 
NA applies if a) chest drain not inserted in first place, b) liver mobilisation not possible (trans-thoracic only) c) one paper 













Stage 2a recommendation 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Make protocol for study available 
 
N N N N N N N N N N N N N N N N 
Use standard, well-defined measures 
for reporting outcome and patient 
characteristics 
 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Report and explain all exclusions 
 
Y N/a N N/a N/a Y Y N/a Y N/a N/a Y Y Y N/a Y 
Report all cases sequentially with 
annotation and explanation of 
changes to indication of procedure 
and when and why they took place 
 
N N/a N N/a N/a N N N/a N N/a N/a N N N N/a N 
Display main outcome graphically 
showing cases sequentially to 
illustrate when changes took place 
 
N N N N N N N N N N N N N N N N 
Informed consent should explain 
status of innovation and consequent 
uncertainties around risk 
 




Y = yes, N = no 




Table 4: Reporting of approval, governance and outcomes in MITTLR studies 
 Number of Studies n=16 (%) 
Ethics approval obtained 5 (31) 
Source of funding declaration 8 (50) 
Conflict of interest 11 (68.5) 
Patient consent obtained 3 (18.8) 






Adverse events 15 (94) 
Clinical outcomes 16 (100) 











Blood loss (ml) Transfusions Conversions Size of tumour 
(mm) 
Indication  Surgical 
margin 
(mm) 
Length of stay 
(days) 
Complications  Observation 
period 
(months) 
Teramoto (13) 3 198-310 50-650 NR NR 17/20 – 14/47 HCC 2-5mm 8-18  0 13-61 
Cloyd (40) 2 NR NR NR NR 23/22– 20/20 HCC negative 3-5 0 7-12 
Ishizawa (39) 10 180-240 100-1200 1 1 NR NR NR NR 2 (not 
specified) 
NR 
Aikawa (48) 1 310 10 0 0 NR CRLM NR 4 0 NR 
Kruger (30) 1 75 20 NR NR 20 HCC NR 2 0 4 
Lee (41) 5 197 (mean) 161 (mean) 0 NR 22 (mean) CRLM (3), Breast Ca 
metastases (1), HCC 
(1) 






8 50-150 50-300 NR 0 6-34 CRLM (5), other (3) 1-11 1-4 0 NR 
Hallet (31) 1 270 300 0 0 40 HCC NR 4 0 NR 
Ogiso (42) 25 90-390 20-2900 1 0 8-49  CRLM (18), other 
metastases  (6), HCC 
(1) 





Schwarz (33) 1 300 100 NR NR 24 CRLM  30 4 0 NR 
Yamashita 
(34) 
1 247 100 0 0 necrosed CRLM 5 NR 0 NR 
Ichida (37) 14 109-477 20-310 NR 1 6-25 Liver mets (11), HCC 
(2), hemangioma (1) 
1-20 6-19 0 NR 
Hirokawa (36) 23 130-427 10-480 NR 1 15-60 HCC (9) 
Other (13) 





Inoue (38) 32 119-427 0-150 4 1 9-60 HCC/ICC (13), 
metastases/others 
(19) 
0-16 6-22 Clavien-Dindo 
classification 
>IIIA (1),  
NR 
Jang (35) 1 420 600 0 0 66 HCC 3 6 0 NR 
Guro (45) 17 NR 500 NR NR NR NR NR 7 NR NR 
 
Appendix 1; Search Strategy 
For Ovid Medline (1946-): 
1     Hepatectomy/ae, co, is, mt [Adverse Effects, Complications, Instrumentation, Methods]  
2     Thoracoscopy/ae, co, is, mt [Adverse Effects, Complications, Instrumentation, Methods]  
3     Thoracic Surgery, Video-Assisted/ae, is, mt [Adverse Effects, Instrumentation, Methods]  
4     hepatectom*.ti,ab,kf.  
5     ((surgery or surgical or thoracic or thorascop*) adj3 liver).ti,ab,kf.  
6     1 or 2 or 3 or 4 or 5  
7     (transthoracic or trans-thoracic).ti,ab,kf.  
8     (transdiaphragmatic or trans-diaphragmatic).ti,ab,kf.  




10   7 or 8 or 9  
11   6 and 10  
 
For Ovid Embase (1974- ):  
1     exp liver resection/  
2     thoracoscopy/  
3     laparoscopy/  
4     video assisted thoracoscopic surgery/  
5     hepatectom*.ti,ab,kw.  
6     ((surgery or surgical or thoracic or thoracoscop*) adj3 liver).ti,ab,kw.  
7     (transdiaphragmatic or trans-diaphragmatic).ti,ab,kw.  
8     (transthoracic or trans-thoracic).ti,ab,kw.  
9     (intercostal or inter-costal).ti,ab,kw.  
10   1 or 2 or 3 or 4 or 5 or 6  
11   7 or 8 or 9  
12   10 and 11  
 
For Web of science: 
1 ((liver or hepatic) SAME (resection* or segmentectomy or surgery or surgical or thoracic or thorascop*)) 
2 Hepatectom* 
3 1 or 2 
4 (trans$thoracic or trans$diaphragmatic or inter$costal) 
5 3 and 4 
 




1 MeSH descriptor: Hepatectomy/ae, co, is, mt [Adverse Effects, Complications, Instrumentation, Methods] 
2 hepatectom*  
3     ((surgery or surgical or thoracic or thorascop* or laporascop*) NEAR (hepatic or liver)  
6     1 or 2 or 3 
7     (transthoracic or trans-thoracic)  
8     (transdiaphragmatic or trans-diaphragmatic)  
9     (intercostal or inter-costal)  
10   7 or 8 or 9 
10   6 and 10 
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